Singapore and Charleston, SC - Novotech, the leading Asia-Pacific biotech specialist CRO, has acquired US CRO NCGS as part of a service expansion program for its global base of clients.
Novotech, which has a reputation for delivering full-service, high-quality expedited clinical trials in Asia-Pacific, can now offer its biotech clients clinical services in the US to support later phase global studies.
NCGS, established in 1984 in South Carolina, is a privately held CRO with a biopharma client base. NCGS has a workforce of about 300 professionals across the US.
Novotech CEO Dr. John Moller said “We are very pleased to acquire such an impressive company with a strong history of quality and delivery in the United States.. The company’s growth is a real credit to the knowledge and expertise of founder Nancy Snowden and the exceptional team she has formed”.
“This is a strategic move to provide US-based expertise and infrastructure for our US clients wanting trials in APAC and the US, and for our APAC clients wanting US clinical programs.”
“Clients will receive seamless service, with a unified approach to systems and SOPs well developed” Moller said.
Nancy C.G. Snowden, Founder and CEO of NCGS said the company was excited about being part of the Novotech operations globally and supporting Novotech’s clients with their US clinical programs. We have a similar cultural fit and focus on excellence so joining Novotech will be seamless for our clients and Novotech’s clients. “Novotech and NCGS have a longstanding collaboration history of over a decade which will also support the seamless integration”, Snowden commented.
“NCGS focuses on complex areas of clinical development; oncology, hematology, infectious disease, and CNS in both adult and pediatric populations.
Our lean organizational structure, nimble operational model with utilization of highly tenured staff have been specifically designed to overcome the challenges inhibiting our industry today. We have the ability to pivot in real time as the needs of the trial evolve.”
Novotech serves biotechs globally leveraging deep relationships built with hundreds of Asia-Pacific sites over the last 25 years. NCGS compliments this with a broad US site base of hundreds of investigators with relationships spanning nearly four decades.
Media contact
Toyna Chin
About Novotech Novotech-CRO.com
Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase.
With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations.
Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies.
Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results
For more information or to speak to an expert team member visit www.Novotech-CRO.com